替格瑞洛用于心脑血管高危患者卒中预防的网络荟萃分析
结果显示替格瑞洛联合阿司匹林显著降低缺血性卒中风险20%(RR 0.80,95%CI 0.71–0.89),但联合抗血小板治疗的大出血相对风险约为单药治疗的两倍。
要点
- 替格瑞洛联合阿司匹林显著降低缺血性卒中风险(RR 0.80,95%CI 0.71–0.89)。
- 替格瑞洛单药对缺血性卒中的影响未达统计学显著(RR 0.88,95%CI 0.77–1.00;P=0.05)。
- 联合抗血小板治疗的大出血相对风险约为单药治疗的两倍,包括颅内出血。
核心结论
- 替格瑞洛联合阿司匹林可能为具有血管危险因素的患者提供更有利的二级卒中预防结局,但获益可能以出血风险增加为代价。
研究设计与样本
- 检索MEDLINE、EMBASE和Cochrane Library至2020年8月1日,使用随机效应模型合并风险比及95%CI。
主要发现
- 与对照相比,替格瑞洛联合阿司匹林显著降低缺血性卒中风险20%(RR 0.80,95%CI 0.71–0.89)。
- 替格瑞洛单药治疗对缺血性卒中的影响无统计学显著性(RR 0.88,95%CI 0.77–1.00;P=0.05)。
- 与阿司匹林单药相比,抗血小板单药治疗的大出血风险范围相似,而联合抗血小板治疗的相对风险高两倍。
- 替格瑞洛联合阿司匹林的全因死亡风险无显著差异(RR 0.99,95%CI 0.91–1.07)。
临床怎么用
- 对于心血管或脑血管病高危患者,可考虑替格瑞洛联合阿司匹林用于二级卒中预防,但需权衡出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Preventive antiplatelet therapy is recommended for patients with cardiac or cerebrovascular atherosclerosis. Ticagrelor has an improved safety and efficacy profile in patients with acute coronary syndrome; however, data regarding stroke prevention remain controversial. We conducted a network meta-analysis to compare ticagrelor with other receptor antagonists (P2Y12) inhibitors and aspirin in monotherapy or combination in the treatment of patients with high risk for cardiovascular or cerebrovascular disease, defined as coronary artery disease, acute coronary syndrome, stroke or transient ischemic attack, or peripheral artery disease. UNLABELLED: Systematic searches of MEDLINE, EMBASE, and the Cochrane Library were conducted until August 1, 2020. Search terms included ticagrelor, AZD 6140, and stroke. The risk of bias was assessed using the Cochrane Collaboration assessment tool. Random-effects model was used to combine risk estimates across trials and risk ratio with 95% CIs served as summary statistics. The influence of individual components was evaluated in an additive network meta-analysis model. The primary efficacy end point was the occurrence of stroke. The safety end points included bleeding and all-cause mortality. UNLABELLED: Twenty-six randomized clinical trials comprising 124 495 patients were analyzed. When compared with controls, ticagrelor plus aspirin significantly reduced the risk of ischemic stroke by 20% (risk ratio, 0.80 [95% CI, 0.71–0.89]). Treatment with ticagrelor monotherapy did not significantly affect ischemic stroke (risk ratio, 0.88 [95% CI, 0.77–1.00]; P=0.05). Compared with aspirin alone, major bleeding was in similar ranges with antiplatelet monotherapies while the relative risk was twice higher with combined antiplatelet therapies. There was no considerable difference in the risk of mortality with ticagrelor plus aspirin (risk ratio, 0.99 [95% CI, 0.91–1.07]). UNLABELLED: Ticagrelor on top of aspirin may provide more favorable outcomes on secondary stroke prevention in patients with vascular risk factors; however, this benefit may come with the price of increased bleeding risk including intracranial bleeding.
引用
- Bálint A, Tornyos D, El Alaoui El Abdallaoui O, et al. Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events. Stroke. 2021. PMID: 34162232. doi:10.1161/STROKEAHA.120.032670
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。